We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current ANNX market cap is 548.42M. The company's latest EPS is USD -1.2593 and P/E is -4.08.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -34.78M | -30.01M | -28.57M | -33.58M | -39.44M |
| Net Income | -32.48M | -27.89M | -25.18M | -29.61M | -34.82M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32.52M | -63.47M | -130.71M | -145.6M | -143.72M |
| Net Income | -38.28M | -70.34M | -130.32M | -141.95M | -134.24M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 203.82M | 297.67M | 304.07M | 406.09M | 378.78M |
| Total Liabilities | 46.98M | 47.12M | 41.66M | 45.01M | 47.22M |
| Total Equity | 156.84M | 250.56M | 262.41M | 361.08M | 331.56M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 49.9M | 355.95M | 287.04M | 285.1M | 297.67M |
| Total Liabilities | 6.37M | 11.67M | 55.13M | 53.9M | 47.12M |
| Total Equity | -100.45M | 344.28M | 231.91M | 231.19M | 250.56M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -97.67M | -121.14M | -28.27M | -49.98M | -81.99M |
| Investing | 72.89M | 70.7M | -77.3M | -173.88M | -219.81M |
| Financing | 17.93M | 135.53M | 32.41M | 156.06M | 156.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -28.36M | -53.09M | -106.11M | -116.31M | -121.14M |
| Investing | -267k | -83.16M | -88.24M | 58.44M | 70.7M |
| Financing | 28.4M | 360.88M | 1.8M | 122.91M | 135.53M |
| Market Cap | 548.42M |
| Price to Earnings Ratio | -4.08 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.43 |
| Price to Book Ratio | 2.19 |
| Dividend Yield | - |
| Shares Outstanding | 106.59M |
| Average Volume (1 week) | 1.43M |
| Average Volume (1 Month) | 1.45M |
| 52 Week Change | 14.59% |
| 52 Week High | 8.40 |
| 52 Week Low | 3.86 |
| Spread (Intraday) | 0.01 (0.19%) |
| Company Name | Annexon Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.annexonbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
